Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at William Blair reduced their FY2018 earnings per share estimates for shares of Exelixis in a report issued on Monday, October 15th, Zacks Investment Research reports. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of $0.94 per share for the year, down from their previous estimate of $1.00. William Blair also issued estimates for Exelixis’ FY2020 earnings at $1.18 EPS.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.19 by $0.22. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The company had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. During the same period in the prior year, the company earned $0.26 earnings per share. The firm’s revenue was up 47.8% on a year-over-year basis.
Shares of EXEL stock traded down $0.45 during mid-day trading on Thursday, hitting $16.67. 4,233,603 shares of the stock were exchanged, compared to its average volume of 4,612,580. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. Exelixis has a 52-week low of $13.42 and a 52-week high of $32.20. The firm has a market cap of $5.18 billion, a P/E ratio of 32.69, a PEG ratio of 1.03 and a beta of 2.29.
In other news, insider Gisela Schwab sold 12,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $17.77, for a total value of $213,240.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Morrissey sold 90,000 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $17.82, for a total transaction of $1,603,800.00. The disclosure for this sale can be found here. Insiders sold a total of 321,500 shares of company stock worth $5,646,160 over the last 90 days. Company insiders own 4.80% of the company’s stock.
A number of large investors have recently made changes to their positions in EXEL. Dimensional Fund Advisors LP raised its stake in Exelixis by 13.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,038,173 shares of the biotechnology company’s stock worth $22,996,000 after acquiring an additional 121,770 shares in the last quarter. Sei Investments Co. increased its stake in Exelixis by 61.0% in the first quarter. Sei Investments Co. now owns 62,457 shares of the biotechnology company’s stock valued at $1,383,000 after purchasing an additional 23,653 shares during the period. Asset Management One Co. Ltd. acquired a new position in Exelixis in the first quarter valued at $248,000. Principal Financial Group Inc. increased its stake in Exelixis by 5.1% in the first quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock valued at $2,016,000 after purchasing an additional 4,445 shares during the period. Finally, UBS Group AG increased its stake in Exelixis by 162.5% in the first quarter. UBS Group AG now owns 393,116 shares of the biotechnology company’s stock valued at $8,707,000 after purchasing an additional 243,361 shares during the period. Hedge funds and other institutional investors own 81.84% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
See Also: Cash Flow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.